Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 1–19 of 19 records
Adalimumab (Humira)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Rheumatoid arthritis and other long-term inflammatory diseases
Pembrolizumab (Keytruda)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Many advanced cancers, by releasing the immune brake on tumour-fighting T cells
Secukinumab (Cosentyx)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Psoriasis, psoriatic arthritis and inflammatory spine disease
Lecanemab (Leqembi)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Early Alzheimer disease, confirmed by an amyloid scan or spinal fluid test
Alirocumab (Praluent)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
High cholesterol after a heart attack, when statins are not enough
Dupilumab (Dupixent)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Eczema, asthma and other diseases driven by the same allergic pathway
Evolocumab (Repatha)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Very high cholesterol that statins alone cannot bring down far enough
Rituximab (Rituxan / MabThera)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Lymphomas and autoimmune diseases driven by B cells
Trastuzumab (Herceptin)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Breast and stomach cancers driven by an over-copied growth receptor
Ustekinumab (Stelara)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Psoriasis, psoriatic arthritis and inflammatory bowel disease
Nivolumab (Opdivo)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Advanced cancers, by restoring exhausted immune cells
Bevacizumab (Avastin)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Several advanced cancers, by cutting off the blood supply a tumour builds for itself
Caplacizumab (Cablivi)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Stopping the microscopic clots of acquired TTP by cutting the tether that platelets are being dragged onto
Emicizumab (Hemlibra)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
A subcutaneous injection, given as rarely as monthly, that stops the joint and muscle bleeds of haemophilia A without replacing the missing clotting factor
Donanemab (Kisunla)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Early Alzheimer disease, with treatment stopped once the plaque is cleared
Idarucizumab (Praxbind)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Switching off the blood thinner dabigatran in an emergency — a serious bleed, or an operation that cannot wait
Ranibizumab (Lucentis)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Leaking abnormal blood vessels growing under the centre of the retina
Romosozumab (Evenity)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
Severe bone thinning in women at high risk of breaking a bone, treated for one year only
Natalizumab (Tysabri)
Antibody medicineApproved in the United States (FDA)Detailed recordUse listed on the medicine record
A monthly infusion for relapsing multiple sclerosis, given under a mandatory monitoring programme